Pharma Pulse

This episode of Pharma Pulse covers the Trump administration’s plan to launch a government-run healthcare website for patients, new data showing gabapentin has become the fifth most prescribed drug in community pharmacies, and promising trial results from a novel gene therapy that slows the progression of Huntington’s disease.

This episode of Pharma Pulse covers new data showing measles vaccine coverage remains below herd immunity thresholds, the FDA’s approval of guselkumab for pediatric plaque psoriasis and psoriatic arthritis, and AbbVie breaking ground on a new API manufacturing site in Illinois.

This episode of Pharma Pulse covers the Trump administration’s 100% tariff on branded drug imports, new research linking pediatric influenza to neurological complications amid vaccination gaps, and AbbVie’s FDA submission for tavapadon, a potential new treatment for Parkinson’s disease.

This episode of Pharma Pulse covers new research showing Medicaid cuts could widen pediatric coverage gaps, clinical trial data on a fixed-dose combination therapy lowering heart failure risk in type 2 diabetes, and Bristol Myers Squibb’s launch of a direct-to-patient program for Sotyktu to improve psoriasis treatment access.

This episode of Pharma Pulse covers the CDC’s unanimous vote to broaden COVID-19 vaccine recommendations for all adults, new data showing the Medicare Part D Senior Savings Model lowers insulin costs and improves care, and Eli Lilly’s investment in a new Houston manufacturing facility to support its fast-growing pipeline.

This episode of Pharma Pulse covers the FDA’s review of a possible link between prenatal acetaminophen use and autism, GSK’s supplemental new drug application to update leucovorin labeling, and Celltrion’s acquisition of an Eli Lilly production facility to expand biologics manufacturing capacity.

This episode of Pharma Pulse covers ACIP’s move toward shared decision-making for COVID-19 vaccines, Pfizer’s acquisition of Metsera to strengthen its obesity and cardiovascular pipelines, and Closed Loop Medicine’s partnership with Wedosify to improve patient adherence to GLP-1 therapies.

This episode of Pharma Pulse covers the CDC’s decision to postpone changes to Hepatitis B vaccine guidance, new research showing value-based care improves visit frequency and consistency for seniors, and Takeda’s partnership with VELA to launch wind-powered transport for medicines.

This episode of Pharma Pulse covers GSK’s $30 billion plan to expand US biopharma production, new evidence that weekly GLP-1 therapies significantly reduce cardiovascular risks, and Roche’s acquisition of 89bio to add the FGF21 analog Pegozafermin to its growing metabolic disease portfolio.

This episode of Pharma Pulse covers new data showing 1 in 6 US parents are delaying or skipping childhood vaccinations, Secretary Robert F. Kennedy Jr.’s move to expand a federal vaccine advisory committee, and survey findings that more than half of healthcare workers are considering leaving their current roles.

This episode of Pharma Pulse covers healthcare advocates’ push for a $50 billion Rural Health Transformation Program, new research showing pneumococcal vaccination gaps among adults with celiac disease, and Novartis’ $5.7 billion licensing agreement with Monte Rosa Therapeutics for protein degrader therapies.

This episode of Pharma Pulse covers new FDA guidance to speed development of non-opioid pain treatments, the FTC’s warning against non-compete agreements for doctors and nurses, and DHL Supply Chain’s acquisition of SDS Rx to strengthen last-mile healthcare delivery.

This episode of Pharma Pulse covers reports of a White House executive order to restrict treatments discovered in China, new data showing robust immune responses from Pfizer and BioNTech’s COVID-19 vaccine in high-risk adults, and Samsung Biologics’ latest US manufacturing deal amid tariff uncertainty.

This episode of Pharma Pulse covers Florida’s plan to roll back school vaccine mandates amid a measles outbreak, President Trump’s renewed focus on limiting direct-to-consumer pharma advertising, and ICER’s latest cost-effectiveness analysis of GLP-1 obesity treatments semaglutide and tirzepatide.

This episode of Pharma Pulse covers Novartis’ acquisition of Tourmaline Bio to advance its cardiovascular candidate Pacibekitug, new research uncovering biological and immunological factors driving flu severity in older adults, and strategies to address the top five reasons patients don’t take their medications.

This episode of Pharma Pulse covers the FDA’s decision to restrict bulk ingredients for compounded GLP-1 therapies, new evidence showing RSV vaccines improve cardiorespiratory outcomes in adults over 60, and pharmacy owners’ concerns over barriers to participating in the Medicaid Drug Price Negotiation Program.

This episode of Pharma Pulse covers Gilead’s groundbreaking on a new technical development hub to accelerate biopharma innovation, the World Health Organization’s decision to add GLP-1s to its Essential Medicines List for diabetes, and new data showing high-dose influenza vaccines reduce heart risks in older adults.

This episode of Pharma Pulse covers President Trump’s appeal to the Supreme Court to preserve pharma tariffs, Sanofi’s 10% stock drop after Amlitelimab failed in Phase III, and new research showing how the COVID-19 pandemic reshaped pneumococcal mortality trends.

This episode of Pharma Pulse covers Amgen’s $600 million investment in a new California R&D center, Novartis’s collaboration with Argo Biopharmaceuticals to boost its cardiovascular pipeline, and new data showing Wegovy outperforming tirzepatide in reducing major adverse cardiovascular events.

This episode of Pharma Pulse covers the FDA’s approval of Sanofi’s Wayrilz for chronic immune thrombocytopenia, evidence that prescription-to-OTC switches of triptans improve migraine care access, and new FDA guidance waiving clinical efficacy studies for most monoclonal antibody biosimilars.

This episode of Pharma Pulse covers rising influenza vaccination rates among historically underserved populations, a new Circurna–GATC Health partnership using AI to advance circular RNA therapies, and fresh research showing many statin-intolerant patients are self-medicating despite limited benefits for lowering LDL cholesterol.

This episode of Pharma Pulse covers new evidence that childhood PCV10 vaccines indirectly protect unvaccinated adults, Eli Lilly’s pause in UK Mounjaro shipments following a major price hike, and the FDA’s Complete Response Letter to Outlook Therapeutics’ resubmission for Lytenava in wet AMD.

This episode of Pharma Pulse covers Susan Monarez’s rejection of White House efforts to remove her as CDC director, new analysis on how long-lasting drug shortages expose systemic supply chain weaknesses, and the FDA’s approval of the first generic liraglutide for weight management.

This episode of Pharma Pulse covers ACOG’s renewed support for COVID-19 vaccination during pregnancy, new real-world evidence confirming the safety of dapagliflozin and empagliflozin for type 2 diabetes, and a partnership between EVERSANA and Waltz Health to improve affordability and patient access.

This episode of Pharma Pulse covers the FDA’s new daily adverse event reporting initiative, the CDC’s appointment of an mRNA vaccine critic to lead its COVID-19 immunization workgroup, and Genentech’s $700 million investment in a North Carolina biologics facility.

This episode of Pharma Pulse covers FDA findings of contamination and safety lapses at Novo’s Bloomington manufacturing plant, the rise of off-label GLP-1 prescribing and its equity challenges, and AbbVie’s acquisition of bretisilocin to advance treatments for major depressive disorder.

This episode of Pharma Pulse covers a $290 million False Claims Act ruling against CVS Caremark, a new report showing most small medical practices fall short on HIPAA compliance, and research revealing why pharmacists underreport adverse drug reactions.

This episode of Pharma Pulse covers the White House–EU agreement on pharmaceutical tariffs, Johnson & Johnson’s $2 billion expansion of its North Carolina manufacturing site, and a new federal rule requiring e-prescribing and prior authorization tools in certified EHR systems.